Antkiewicz-Michaluk Lucyna, Romańska Irena, Wąsik Agnieszka, Michaluk Jerzy
Department of Neurochemistry, Institute of Pharmacology Polish Academy of Sciences, 12 Smętna Street, 31-343, Kraków, Poland.
Neurotox Res. 2017 Jul;32(1):94-106. doi: 10.1007/s12640-017-9715-z. Epub 2017 Apr 3.
Biogenic amines such as norepinephrine, dopamine, and serotonin play a well-described role in the treatment of mood disorders especially depression. Animal models are widely used to study antidepressant-like effect in rodents; however, it should be taken into account that pharmacological models do not always answer to the complexity of the disease processes. This study verified the behavioral (forced swim test (FST), locomotor activity test) and neurochemical effects (monoamines metabolism) of a low dose of clonidine (0.1 mg/kg i.p.) which was used as an experimental model of depression. In such pharmacological model, we investigated the antidepressant-like effect of an endogenous neuroprotective amine, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) administered in a dose of 25 mg/kg (i.p.) before clonidine in the behavioral and neurochemical tests carried out in rats. The behavioral study has shown that clonidine produced depression in the locomotor activity test but did not cause pro-depressive effect in the FST. 1MeTIQ produced antidepressant-like effect in the FST and completely antagonized clonidine-induced sedation in the locomotor activity test. Neurochemical data demonstrated that clonidine produced a significant inhibition of monoamine metabolism in the central nervous system. The release of dopamine, noradrenaline, and serotonin as well as the rate of their metabolism were diminished in the investigated brain structures (frontal cortex, hypothalamus, and striatum). 1MeTIQ completely antagonized the clonidine-induced depression of monoaminergic systems and restored their levels to the control values. 1MeTIQ as an endogenous neuroprotective compound with a distinct antidepressant-like activity in rodents produces hope on the efficiency of antidepressant medicines for future practical clinical use.
生物胺如去甲肾上腺素、多巴胺和血清素在情绪障碍尤其是抑郁症的治疗中发挥着众所周知的作用。动物模型被广泛用于研究啮齿动物的抗抑郁样作用;然而,应该考虑到药理学模型并不总是能应对疾病过程的复杂性。本研究验证了低剂量可乐定(0.1毫克/千克腹腔注射)的行为学(强迫游泳试验(FST)、自发活动试验)和神经化学效应(单胺代谢),该剂量可乐定被用作抑郁症的实验模型。在这种药理学模型中,我们在对大鼠进行的行为学和神经化学试验中,研究了内源性神经保护胺1-甲基-1,2,3,4-四氢异喹啉(1MeTIQ)在可乐定之前以25毫克/千克(腹腔注射)剂量给药时的抗抑郁样作用。行为学研究表明,可乐定在自发活动试验中产生抑郁作用,但在FST中未引起促抑郁作用。1MeTIQ在FST中产生抗抑郁样作用,并在自发活动试验中完全拮抗可乐定诱导的镇静作用。神经化学数据表明,可乐定对中枢神经系统的单胺代谢有显著抑制作用。在所研究的脑结构(额叶皮质、下丘脑和纹状体)中,多巴胺、去甲肾上腺素和血清素的释放及其代谢率均降低。1MeTIQ完全拮抗可乐定诱导的单胺能系统抑制,并将其水平恢复到对照值。1MeTIQ作为一种在啮齿动物中具有明显抗抑郁样活性的内源性神经保护化合物,为未来抗抑郁药物在实际临床应用中的有效性带来了希望。